Mitobronitol (Myelobromol; DBM) is a brominated analog of mannitol. Mitobronitol is an anticancer agent classified as an alkylating agent. Mitobronitol shows myelosuppression effect that significantly reduced risk for several complications of allogeneic bone marrow transplantation in accelerated chronic granulocytic leukemia [1] [2].

Mitobronitol (850 mg/kg; i.p.; single dose) improves spleen cells to mitogens and enhances thymus regeneration in mice model [2]. Animal Model: Female BALB/c mice (8-10 weeks old) [2] Dosage: 850 mg/kg; 1500 mg/kg (suspended in 5% Tween 80 in saline, 0.5 mL) Administration: Intraperitoneal injection; single dose Result: Showed effect on the in vitro proliferative response of spleen cells to mitogens at 850 mg/kg. Enhanced thymus regeneration and was earlier than control, with the starting resititution time-course of 2 weeks and subtotal resititution time course of 3 weeks under 1500 mg/kg dose.